ERS GENOMICS LIMITED

Ers Genomics Limited is a world-leading licensing organisation that provides commercial access to the core CRISPR/Cas9 patent portfolio. Built on the Nobel-prize-winning work of Emmanuelle Charpentier and Jennifer Doudna, the company's portfolio comprises more than 85 issued patents covering over 80 jurisdictions, making it the most foundational collection of CRISPR/Cas9 intellectual property available to researchers, biotech firms and pharmaceutical developers.

By acting as the global gateway to this essential technology, Ers Genomics enables its partners to harness the transformative power of gene-editing for a wide range of applications, from basic science to therapeutic development. The firm's co-founder, Emmanuelle Charpentier, is also a co-owner of the patents and a 2020 Nobel laureate, underscoring the scientific credibility and strategic importance of the licences on offer. Ers Genomics therefore serves as a critical bridge between cutting-edge discovery and commercial realisation of CRISPR-based solutions.